Literature DB >> 16640743

Neuropathic pain: are we out of the woods yet?

J Cavenagh1, P Good, P Ravenscroft.   

Abstract

Patients suffering from neuropathic pain continue to pose challenges in clinical practice. This descriptive review discusses the continuing debate on the definition and concerns about increasing incidence of neuropathic pain. The clinical features of neuropathic pain are outlined, and the current understanding of the possible mechanisms of neuropathic pain is highlighted. Current management strategies are reviewed, and future advances in our understanding of the mechanisms, accurate clinical diagnosis and more effective treatment strategies are eagerly awaited.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16640743     DOI: 10.1111/j.1445-5994.2006.01046.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  9 in total

1.  Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.

Authors:  Young-Chang P Arai; Takako Matsubara; Kazuhiro Shimo; Katsutoshi Suetomi; Makoto Nishihara; Takahiro Ushida; Kunio Kobayashi; Chiharu Suzuki; Akiko Kinoshita; Miki Kondo; Satuki Matsubara; Ruiko Hayashi; Yukio Tohyama; Kikuyo Nishida; Maki Arakawa
Journal:  J Anesth       Date:  2010-03-10       Impact factor: 2.078

2.  Thermal sensitivity across ages and during chronic fentanyl administration in rats.

Authors:  Jeremiah D Mitzelfelt; Christy S Carter; Drake Morgan
Journal:  Psychopharmacology (Berl)       Date:  2013-07-31       Impact factor: 4.530

3.  Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat.

Authors:  Elizabeth K Joseph; Jon D Levine
Journal:  J Pain       Date:  2009-02-23       Impact factor: 5.820

4.  Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.

Authors:  E M L Smith; H Pang; C Ye; C Cirrincione; S Fleishman; E D Paskett; T Ahles; L R Bressler; N Le-Lindqwister; C E Fadul; C Loprinzi; C L Shapiro
Journal:  Eur J Cancer Care (Engl)       Date:  2015-11-25       Impact factor: 2.520

5.  Adverse cognitive effect of gabapentin in individuals with spinal cord injury: preliminary findings.

Authors:  Kazuko Shem; Steven Barncord; Kara Flavin; Manoj Mohan
Journal:  Spinal Cord Ser Cases       Date:  2018-01-23

6.  Association between extracellular signal-regulated kinase expression and the anti-allodynic effect in rats with spared nerve injury by applying immediate pulsed radiofrequency.

Authors:  Chun-Chang Yeh; Zhi-Fu Wu; Jui-Chieh Chen; Chih-Shung Wong; Chi-Jung Huang; Jinn-Shyan Wang; Chih-Cheng Chien
Journal:  BMC Anesthesiol       Date:  2015-06-16       Impact factor: 2.217

7.  Identification of differentially expressed genes by gabapentin in cultured dorsal root ganglion in a rat neuropathic pain model.

Authors:  Ji Hye Heo; Seung Ha Lee; Kyung Ha Chang; Eun Hye Han; Seung Gwan Lee; Dal Woong Choi; Suhng Wook Kim
Journal:  Biomol Ther (Seoul)       Date:  2013-03       Impact factor: 4.634

8.  Molecular mechanisms underlying the effects of acupuncture on neuropathic pain.

Authors:  Ziyong Ju; Huashun Cui; Xiaohui Guo; Huayuan Yang; Jinsen He; Ke Wang
Journal:  Neural Regen Res       Date:  2013-09-05       Impact factor: 5.135

9.  The efficacy of gabapentin combined with opioids for neuropathic cancer pain: a meta-analysis.

Authors:  Hainan Bao; Zhouyue Wu; Qinxin Wang; Jiatong Wang; Li Zhang; Lingtong Meng; Feng Han
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.